久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

 
 
 

New studies on HIV treatment as prevention

2012-04-26 15:49

 

Get Flash Player

Download

New studies on HIV treatment as prevention

Recent studies have shown that antiretroviral drugs can be used not only to treat HIV, but also to prevent infection in the first place. It's called pre-exposure prophylaxis or PrEP for short. Now, the western US state of California is launching new studies to determine PrEP's effectiveness beyond clinical trials and out in the real world.

Treatment as prevention has been shown to be highly successful in clinical trials. But will it work for people in high risk groups as they go about their daily lives? Will they adhere to the drug regimen even if it's taking only one pill a day?

These are some of the questions the California HIV/AIDS Research Program hopes to answer with three new studies. Mitchell Warren, head of the AIDS advocacy group AVAC, said these are "demonstration studies."

"These are not randomized controlled trials where we're telling people you may get placebo, you may get the active drug. And even if you get the active drug we don't know if it works. These are studies that are going to work with people in communities in California. People who are at risk. [They] are going to be explained that we think this product works based on these clinical trials, but only if you use [it]. And provide it to a small number of people to really better understand the safety and effectiveness in areas outside of clinical trials," he said.

MSM & transgenders

The studies focus on groups where HIV infections are rising rapidly.

Warren said, "All of these activities in California are focused on men who have sex with men and transgender women. And that is entirely understandable and appropriate given the epidemic in the United States. That is the leading area of need. At the same time we really hope as advocates that these demonstration projects in California are the first of many and that many more will look at other populations."

Those taking part in the study are being asked to follow what would appear to be a very simple drug regimen.

"It is a daily dose and it is a combined drug. It's a single pill, but with both active tenofovir and emtricitabine. And it is the same dose that is provided to people who are infected with HIV, who use the same pill for treatment. So the recommendation that was studied in the trial was the same single pill every day," he said.

Daily dose

However, Warren said pre-exposure prophylaxis is only effective if people take the pill. So the studies will also examine why people may skip doses, even if they only have to swallow one pill a day.

"People who took this pill consistently had high levels, an excess of 70 percent reduction of risk. People who didn't take the pill consistently didn't get any benefit at all. There was no added protection," he said.

When antitrovirals first came on the scene in the early and mid-1990s, people had to take dozens of pills a day. They had to take them at very specific times, sometimes with food, sometimes without. They often had very bad side effects, including nausea. There were even conditions called "buffalo hump" and "Crix belly," where body fat would build up behind the neck or on the abdomen. So, while lives were being saved, treatment could make people feel pretty sick.

Warren said it's much different today.

"We also have to remember the incredible scientific advances – from the 80s when getting HIV inevitably meant a very short life and a very painful disease in death – to a period of early antiretroviral therapy where we had drugs that were very difficult to take and very toxic, but they could save your life if you could withstand that – to a point now where people can take one or two pills a day. Much safer, much less toxic. We're in a very different place," he said.

In May, the US Food and Drug Administration will review the PrEP research. It could lead to greater access to prevention as treatment and provide accurate information to healthcare providers, insurance companies and potential users.

placebo: a substance containing no medication and prescribed or given to reinforce a patient's expectation to get well 安慰劑

Related stories:

Better treatment for HIV-positive pregnant women

Much progress, much to do on HIV

New guidelines would help ensure HIV treatment

Hepatitis C kills more Americans than HIV/AIDS

(來源:VOA 編輯:旭燕)

 
中國日報網英語點津版權說明:凡注明來源為“中國日報網英語點津:XXX(署名)”的原創作品,除與中國日報網簽署英語點津內容授權協議的網站外,其他任何網站或單位未經允許不得非法盜鏈、轉載和使用,違者必究。如需使用,請與010-84883561聯系;凡本網注明“來源:XXX(非英語點津)”的作品,均轉載自其它媒體,目的在于傳播更多信息,其他媒體如需轉載,請與稿件來源方聯系,如產生任何問題與本網無關;本網所發布的歌曲、電影片段,版權歸原作者所有,僅供學習與研究,如果侵權,請提供版權證明,以便盡快刪除。

中國日報網雙語新聞

掃描左側二維碼

添加Chinadaily_Mobile
你想看的我們這兒都有!

中國日報雙語手機報

點擊左側圖標查看訂閱方式

中國首份雙語手機報
學英語看資訊一個都不能少!

關注和訂閱

本文相關閱讀
人氣排行
搜熱詞
 
 
精華欄目
 

閱讀

詞匯

視聽

翻譯

口語

合作

 

關于我們 | 聯系方式 | 招聘信息

Copyright by chinadaily.com.cn. All rights reserved. None of this material may be used for any commercial or public use. Reproduction in whole or in part without permission is prohibited. 版權聲明:本網站所刊登的中國日報網英語點津內容,版權屬中國日報網所有,未經協議授權,禁止下載使用。 歡迎愿意與本網站合作的單位或個人與我們聯系。

電話:8610-84883645

傳真:8610-84883500

Email: languagetips@chinadaily.com.cn

主站蜘蛛池模板: 亚洲成人中文字幕 | 欧美日韩国产免费一区二区三区 | 亚洲视频观看 | 免费看一级 | 欧美一区不卡二区不卡三区 | 男人天堂网在线 | 天天澡天天碰天天狠伊人五月 | 精品国产一区二区二三区在线观看 | 久久国产精品99久久久久久牛牛 | 五月桃花网婷婷亚洲综合 | 2017天天爽夜夜爽精品视频 | 欧美亚洲日本 | 成人18免费视频 | 青青草国产免费国产是公开 | 久草福利资源 | 伊人久久在线 | 一本久道久久综合中文字幕 | 欧美黄网站免费观看 | 日本精品夜色视频一区二区 | 亚洲第一视频在线播放 | 三级视频在线观看 | 狠狠色丁香久久婷婷综合_中 | 中文字幕av一区二区三区 | 日韩一级片在线观看 | 国产麻豆福利a v在线播放 | 国产午夜精品不卡观看 | 亚洲国产高清视频在线观看 | 9久9久女女热精品视频免费观看 | 国产成人午夜福在线观看 | 日本妞xxxxxxxxx69 | 久久综合九九 | 男女男精品视频免费观看 | 国产欧美另类久久精品91 | 91久久精品青青草原伊人 | 亚洲二三区 | 国产精品毛片天天看片 | 手机在线黄色 | 欧美成人免费一级人片 | 久草视频福利在线观看 | 欧美色另类 | 好吊妞998视频免费观看在线 |